#142 – Does oseltamivir harm critically ill patients? The REMAP-CAP results
Shownotes
Does oseltamivir harm critically ill patients with influenza? In this Breakpoints and Communicable collaboration, Erin McCreary and Josh Davis are joined by Steve Webb and Steve Tong to discuss the REMAP-CAP trial results that are challenging a long-standing intensive care practice. Together, they review the study design, key findings, and implications for clinical care, while highlighting the importance of randomized clinical trials in shaping evidence-based medicine. At the time of recording, the REMAP-CAP results were available as a preprint.
Resources:
· REMAP-CAP: A Randomised, Embedded, Multi-factorial, Adaptive Platform Trial for Community-Acquired Pneumonia, https://www.remapcap.org/
References:
1. Murthy S, et al. Oseltamivir for Critically Ill Patients with Influenza: A Randomised Trial. Lancet 2026. Preprint http://dx.doi.org/10.2139/ssrn.7172531
Learn more about the Society of Infectious Diseases Pharmacists: https://protect2.fireeye.com/v1/url?k=4063f96c-1ff8c1be-4063b7ad-867b1e11f55a-4ebd02e8eaa2fcc2\&q=1\&e=caf63b63-0143-4fa9-a81b-8d3031af3116\&u=https%3A%2F%2Fsidp.org%2FAboutSIDP – About
Instagram: @SIDPharm ( https://www.instagram.com/sidpharm/) or @breakpointspodcast_sidp (https://www.instagram.com/breakpointspodcast_sidp/) https://www.instagram.com/breakpointspodcast_sidp/?hl=en
Facebook: https://www.facebook.com/sidprx
LinkedIn: https://www.linkedin.com/company/sidp/https://www.linkedin.com/company/sidp/
SIDP welcomes pharmacists and non-pharmacist members with an interest in infectious diseases, learn how to join here: https://sidp.org/Become-a-Member
Find out more at https://sidp.pinecast.co